Nomogram for predicting the benefit of neoadjuvant chemoradiotherapy for esophageal cancer: A SEER-Medicare analysis.

被引：0
|
作者：
Eil, Robert
Diggs, Brian S.
Wang, Samuel J.
Dolan, James P.
Hunter, John G.
Thomas, Charles R.
机构：
[1] Oregon Hlth & Sci Univ, Dept Surg, Portland, OR 97201 USA
[2] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
[3] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4073
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Nomogram for Predicting the Benefit of Neoadjuvant Chemoradiotherapy for Patients With Esophageal Cancer A SEER-Medicare Analysis
    Eil, Robert
    Diggs, Brian S.
    Wang, Samuel J.
    Dolan, James P.
    Hunter, John G.
    Thomas, Charles R.
    CANCER, 2014, 120 (04) : 492 - 498
  • [2] Effect of Chemoradiotherapy before and after Surgery for Esophageal Cancer: A SEER-Medicare Analysis
    Hong, J. C.
    Koong, A. C.
    Chang, D. T.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 81 (02): : S314 - S314
  • [3] Chemoradiotherapy Before and After Surgery for Locally Advanced Esophageal Cancer: A SEER-Medicare Analysis
    Hong, Julian C.
    Murphy, James D.
    Wang, Samuel J.
    Koong, Albert C.
    Chang, Daniel T.
    ANNALS OF SURGICAL ONCOLOGY, 2013, 20 (12) : 3999 - 4007
  • [4] Chemoradiotherapy Before and After Surgery for Locally Advanced Esophageal Cancer: A SEER-Medicare Analysis
    Julian C. Hong
    James D. Murphy
    Samuel J. Wang
    Albert C. Koong
    Daniel T. Chang
    Annals of Surgical Oncology, 2013, 20 : 3999 - 4007
  • [5] Rate and Determinants of Completing Neoadjuvant Chemotherapy in Medicare Beneficiaries With Bladder Cancer: A SEER-Medicare Analysis
    Hugar, Lee A.
    Yabes, Jonathan G.
    Turner, Robert M., II
    Fam, Mina M.
    Appleman, Leonard J.
    Davies, Benjamin J.
    Jacobs, Bruce L.
    UROLOGY, 2019, 124 : 191 - 197
  • [6] Treatment workload by stage and subtype in patients with breast cancer: A SEER-Medicare analysis.
    Cheng, Alex
    Warner, Jeremy Lyle
    Levy, Mia Alyce
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [7] Re: Rate and Determinants of Completing Neoadjuvant Chemotherapy in Medicare Beneficiaries with Bladder Cancer: A SEER-Medicare Analysis
    Griebling, Tomas L.
    JOURNAL OF UROLOGY, 2020, 204 (02): : 363 - 363
  • [8] Advanced Pancreatic Cancer Treated With Neoadjuvant Therapy and Surgical Resection: A SEER-Medicare Analysis
    Smith, J. K.
    Ng, S. C.
    Simons, J. P.
    Shah, S. A.
    McDade, T. P.
    Tseng, J. F.
    PANCREAS, 2010, 39 (08) : 1348 - 1348
  • [9] Nomogram for Predicting Pathologic Response Following Neoadjuvant Chemotherapy or Chemoradiotherapy in Patients with Esophageal Cancer
    Ribeiro Jr, Ulysses
    ANNALS OF SURGICAL ONCOLOGY, 2023, 30 (04) : 1945 - 1947
  • [10] Nomogram for Predicting Pathologic Response Following Neoadjuvant Chemotherapy or Chemoradiotherapy in Patients with Esophageal Cancer
    Ulysses Ribeiro
    Annals of Surgical Oncology, 2023, 30 : 1945 - 1947
12345